Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.10
-0.0097-0.87%
Volume:102.21K
Turnover:113.80K
Market Cap:70.76M
PE:-3.46
High:1.14
Open:1.12
Low:1.10
Close:1.11
52wk High:3.82
52wk Low:0.7811
Shares:64.31M
Float Shares:52.11M
Volume Ratio:3.85
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3175
EPS(LYR):-0.3175
ROE:-65.70%
ROA:-30.80%
PB:0.83
PE(LYR):-3.46

Loading ...

iBio Updates Governance Deadlines for 2026 Annual Meeting

TIPRANKS
·
Jul 18

Ibio is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 02

Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained

TIPRANKS
·
Jul 02

iBio Highlights Promising New Preclinical Obesity Antibody Data

TIPRANKS
·
Jul 01

Ibio Reports Single Dose of Ibio-610 Achieved Near-complete Active Activin E Inhibition Through Eight Weeks in Obese Nhp Study

THOMSON REUTERS
·
Jul 01

Ibio Says Single-dose Ibio-610 Cuts Active Activin E 98% Through Eight Weeks in Obese Primate Study

Reuters
·
Jul 01

Savara COO Robert Lutz to take CFO role as Lowrance steps down for health reasons

Reuters
·
Jun 09

iBio Initiated at Outperform by Raymond James

Dow Jones
·
Jun 09

Raymond James Initiates iBio at Outperform With $5 Price Target

MT Newswires Live
·
Jun 08

iBio initiated with an Outperform at Raymond James

TIPRANKS
·
Jun 08

Ibio Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $6

THOMSON REUTERS
·
Jun 05

B. Riley Initiates iBio at Buy With $6 Price Target

MT Newswires Live
·
Jun 05

U.S. RESEARCH ROUNDUP-Chipotle Mexican Grill, Honeywell, Tesla

Reuters
·
Jun 05

iBio executives present at Jefferies Global Healthcare Conference

Reuters
·
Jun 03

iBio to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire
·
Jun 03

iBio doses first patient in Phase 1 trial of obesity drug candidate IBIO-600

Reuters
·
Jun 02

Ibio Becomes a Clinical-Stage Company With First Participant Dosed in Phase 1 Clinical Trial of Ibio-600 in Adults With Obesity

THOMSON REUTERS
·
Jun 02

IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar

TIPRANKS
·
May 30

LifeSci Capital Remains a Buy on Ibio (IBIO)

TIPRANKS
·
May 16

iBio files Form 3 as director Elizabeth Stoner reports no beneficial ownership

Reuters
·
May 15